Navigation Links
Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Date:9/18/2007

lower plasma insulin levels than both after three hours. The data showed that VIAject(TM) provides better postprandial blood glucose control with less hyperglycemia in the first three hours after the meal and less risk of hypoglycemia in the next five hours as compared to Humulin(R) R and Humalog(R). Further data is available in the investor relations section of Biodel's website under "Calendar of Events" at http://www.biodel.com.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in Phase I clinical trials and two osteoporosis

product candidates in pre-clinical studies. For further information regarding Biodel, please visit the Company's website.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other then statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward- looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all fo
'/>"/>

SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, ... in critical areas, announced the closing of an underwritten public ... purchase up to an aggregate 3,500,000 shares of common stock, ... per warrant.  The warrants have a per share exercise price ...
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ...
(Date:12/24/2014)... December 23, 2014 SoundConnect’s ... to introduce cutting edge communication technology, provide continued ... upgrades. This webinar series demonstrates online communication features ... leverage web conferencing’s most innovative and powerful tools. ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
...   Hospitals, health systems to benefit,from ... and other,performance management solutions Elsevier ... products,and services, has struck an exclusive partnership with ... learning solutions for process,improvement. Elsevier will market ...
... carbon, has the potential to make consumer electronic devices ... shrinking scale of electronics, also make graphene difficult to ... In September 2010, a UCLA research team ... and were able to fabricate graphene transistors with unparalleled ...
... 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ) ... agreements with various institutional investors and its CEO for ... in a registered direct offering at $8.85 per share, ... of the offering, before deducting expenses, are expected to ...
Cached Biology Technology:Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 2Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 3Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 4UCLA team reports scalable fabrication of self-aligned graphene transistors, circuits 2Pharmacyclics Announces Results of Registered Direct Offering 2Pharmacyclics Announces Results of Registered Direct Offering 3
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
(Date:12/17/2014)... 16, 2014 Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... Chemical Sensor Market 2015-2019" report to their offering. ... One major trend upcoming in this market is the ... sensors help in recording of patient data for quick ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... new bacterium in an immune-compromised patient, according to a ... belongs to the family Acetobacteraceae and includes bacteria common ... industry, such as vinegar-making. "This is the first ... of the Acetobacteraceae," according to the article. ...
... single atom from the molecular structure of vancomycin aglycon, ... cell wall synthesis, significantly increasing the drug's spectrum of ... common strains of enterococci have become resistant to vancomycin ... This re-engineering effort could help make the drug more ...
... flu is bad enough for healthy people, but the ... weakened immune systems, such as patients on chemotherapy. A ... of Philadelphia will support research to determine how adults ... vulnerable to influenza, and will seek better ways to ...
Cached Biology News:Soil-bound prions that cause CWD remain infectious 2Scientists re-engineer a well-known antibiotic to counter drug resistance 2How can we protect patients with weakened immune systems from influenza? 2How can we protect patients with weakened immune systems from influenza? 3
... provides a genome-wide microRNA (miRNA) expression profiling ... design, which enable highly sensitive and specific ... standard arrays for mature miRNA of all ... the Sanger miRBase database (Release 8.2). Our ...
... Microarrays designed for immunological studies, vaccine ... the flexible and powerful Paraflo microfluidic ... available as part of our comprehensive ... Custom Probe Content Probe content ...
... Custom peptide microarrays designed for ... serum samples and built on the ... platform. Thousands of customer specified sequences ... Sciences can provide assistance with custom ...
... the first time, you can identify and ... efficiently without interferences. The Agilent Multiple Affinity ... multiple high-abundant proteins from human serum, plasma, ... one device. With this revolutionary system, you ...
Biology Products: